SCHEMBL6475600

SCHEMBL6475600

Nc1ccc(C(F)(F)F)cc1CSc1nc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
HPGD P15428 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
MAPT P10636 3/20 0.52
LMNA P02545 2/20 0.52
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
BCHE P06276 1/20 0.49
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474677 0.84 NPC1 (0.64) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL6480538 0.81 ATP4A (0.57) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL6482715 0.81 NPC1 (0.56) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL6480868 0.81 NPC1 (0.69) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL31325540 0.80 RAB9A (0.72) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
Bromide SCHEMBL10768702 0.79 NPC1 (0.68) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL6481780 0.78 SMN1; SMN2 (0.65) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL6482116 0.77 ATP4A (0.44) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL6474267 0.76 ATP4A (0.61) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL6474777 0.75 RAB9A (0.55) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
EP-0204215-A1 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines G.D. Searle & Co. (US) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 NPC1 363/4885RAB9A 486/4885HPGD 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.